GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patientsSecond investigator-initiated trial to evaluate efti in earlier stage disease where its unique activation of a broad anti-cancer immune response may drive optimal benefit and high pathologic response rates SYDNEY, AUSTRALIA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a ...

~Patient Recruitment Closed~LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in its Phase 2/3 clinical trial, COMBAT-ALS, evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 patients have been randomized across two treatment ...

Study led by CureShankAims to characterize the direct and indirect burden of PMS to patients, caregivers, and US healthcare system MADRID and CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, is proud to announce its participation as a sponsor of the first-ever Phelan-McDermid syndrome (PMS) burden of illness study. The study is led by CureShank, a research advocacy organ ...

Presentation Highlighted Data Supporting Clinical Benefit of GTx-104 Compared to Orally Administered Nimodipine in the Treatment of aneurysmal Subarachnoid Hemorrhage (aSAH)PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aSAH patients, to ...

公司活动安排 - 首席财务官Douglas Larson将参加2025年10月9日在纽约举行的ROTH第四届年度医疗保健机会会议 [1] - 会议期间可为投资者安排一对一会议 需通过Roth Capital Partners代表预约 [2] 公司业务概况 - 公司处于商业化阶段的医疗设备和生物制药领域 专注于利用内源性和外源性一氧化氮改善患者生活 [3] - 目标治疗领域包括呼吸系统疾病、神经系统疾病和实体瘤 [3] - 首款系统LungFit PH已获得FDA批准和CE认证 用于治疗足月和近足月新生儿缺氧性呼吸衰竭 [3] 产品研发管线 - 正在进行其他LungFit系统的临床试验 针对病毒性社区获得性肺炎（包括COVID-19）和非结核分枝杆菌等严重肺部感染 [3] - 与耶路撒冷希伯来大学合作推进临床前项目 专注于治疗自闭症谱系障碍和其他神经系统疾病 [4] - 关联公司Beyond Cancer正在研究超高浓度一氧化氮联合专有递送系统 用于治疗某些实体瘤 [4] 产品技术特性 - LungFit是无钢瓶相位流量发生器输送系统 被FDA认定为医疗器械 [5] - 呼吸机兼容版本可从环境空气中按需生成一氧化氮 浓度范围1 ppm至80 ppm [5] - 可替代大型高压一氧化氮钢瓶 显著减少医院库存和存储需求 通过消除二氧化氮净化步骤提高安全性 [5] - 高浓度模式（≥80 ppm）可潜在治疗医院内急性肺部感染和家庭环境中慢性难治性肺部感染 [6] - 无钢瓶设计使得家庭一氧化氮治疗成为可能 [6] 产品监管状态 - LungFit PH已在美国、欧盟和全球多国获批商业用途 [7] - 其他LungFit系统尚未获批商业用途 仅限研究使用 [7]

公司收购与战略布局 - 辉瑞宣布收购临床阶段生物制药公司 交易金额最高达70亿美元 [1] - 收购目标为进入目前由礼来和诺和诺德主导的减肥药市场 [1] 行业竞争格局 - 减肥药市场目前被礼来和诺和诺德两家公司主导 [1] - 辉瑞通过收购临床阶段公司寻求进入该 lucrative 市场 [1]

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27th thro. ...

Accessibility StatementSkip Navigation Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic macular edema PRINCETON, N.J., Sept. 22, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company advancing medicines that modulate the melanocortin receptor system, today announced the achievement of a research milestone under its collaboration with Boehringer Ingelheim. Thi ...

PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clinical trials oral presentation, one oral presentation, and three poster sessions will be shared at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2025, taking place in Minneapolis, MN from September 26 - 29, 2025. Late Breaking Clinical Trials Oral ...

Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone and kidney biomarkers All patients completed the 12-week AvailTM trial and 94% entered the OLE Once-weekly canvuparatide was generally well tolerated, with no treatment-related serious adverse events or discontinuations during the 12-week trial Preparation underway to initiate Phase 3 trial in 2026 Company to ...